Glenmark and Lotus enter into an exclusive licensing agreement for commercialising Ryaltris in Singapore, Hong Kong and Vietnam. Under the terms of the agreement, Glenmark will be responsible for the manufacturing and supply of Ryaltris, while Lotus International will be responsible for the commercialisation of the product across these markets, Glenmark informed via a statement.
In addition, the statement said that Glenmark will receive an upfront payment as well as regulatory and sales-based milestone payments from Lotus. Ryaltris, developed by Glenmark, is a novel, fixed-dose combination nasal spray of an anti-histamine (olopatadine hydrochloride) and a steroid (mometasone furoate), indicated for treatment of symptoms associated with Allergic Rhinitis (AR) in adults and pediatric patients, 12 years of age and older.
The statement quoted Petar Vazharov, Chief Executive Officer, Lotus as saying, “….. This is the first brand product to be included in our respiratory portfolio with strong clinical data and IP protection…..”
Further, according to the statement, AR is a heterogeneous disorder that, despite its high prevalence, is often undiagnosed. Prevalence of AR is 4.2 per cent in Hong Kong, 4.9 per cent in Singapore and 12.3 per cent in Vietnam. Being a topical therapy, Ryaltris offers many advantages over oral therapies, such as delivering greater concentrations of drug to the receptor sites at the source of the allergic inflammation and reduced risk of systemic side effects.